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ABSTRACT 
 
 
  
 The purpose of this project is to evaluate the impact of stem cells, as an innovative 
technology, on society. This project provides a discussion of the various types of stem cells used 
in research, applications of these stem cells to the field of medicine, the ethics surrounding the 
use of stem cells, and the legislation that has been imposed in the US and internationally as a 
result of stem cell research.  With consideration of the information above, despite ethical 
drawbacks, this project advocates stem cell research, embryonic and adult, for the betterment of 
society as a whole.  
 3 
TABLE OF CONTENTS 
 
Signature Page ……………………………………………………………………..  1 
Abstract …………………………………………………………………………….  2 
Table of Contents …………………………………………………………………..  3 
Project Objective ……………………………………...……………………………  4 
Chapter-1:   Stem Cell Types and Sources .……...…………………………………  5 
Chapter-2:   Stem Cell Applications ..……………………………………………..  18 
Chapter-3:  Stem Cell Ethics ………………………………………………………  32 
Chapter-4:  Stem Cell Legalities ……………………………………….………….  48 
Project Conclusions ………………………………….………….…………………  69 
 4 
PROJECT OBJECTIVES 
 
 
 The purpose of this Interdisciplinary Qualifying Project (IQP) is to examine the subject 
of stem cells, and to assess the impact of this novel and revolutionary technology on society.  
The objective of Chapter-1 is to provide a basis for further stem cell discussion. Thus, this 
chapter contains content on how stem cells are classified, where stem cells are isolated from, and 
the various types of stem cells and their potencies.  Chapter-2’s purpose is to document the types 
of experiments that stem cells have been effectively used for. This chapter distinguishes animal 
experiments from human clinical trials, as well as future experiments from well-documented 
success stories, as an aid for realistically focusing the subsequent chapter on ethics.  Chapter-3’s 
purpose is to study the ethics surrounding stem cell research, particularly embryonic stem cell 
research, while Chapter-4 examines the U.S. and international laws governing stem cell use.  
Finally, this project ends with the author’s conclusion on the use of stem cells and which laws 
best represent the author’s point of view. 
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CHAPTER-1:  STEM CELL TYPES AND SOURCES 
 
Many misinformed individuals still believe that only one type of stem cell exists, and 
usually they are referring to the type that destroys an embryo to obtain them. In reality, the 21
st
 
century has brought with it many different varieties of stem cells, each with their own diverse 
origin, potentials, and uses.  Stem cell types can be divided into four main categories: embryonic 
stem (ES) cells, induced pluripotent stem (iPS) cells, adult stem cells (ASCs), and 
parthenogenetic ES cells.  The purpose of this chapter is to document the various types of stem 
cells currently known, and to describe their potencies. 
The term “stem cell” dates back to William Sedgwick, who used it to describe the 
regenerative properties of plants in 1886 (Charmany, 2004).  Thus, despite stem cells’ sudden 
rise in popularity, the idea of stem cells as a source of new replacement cells has actually been 
around for over a century.  But before jumping into describing stem cells, an understanding of 
basic cell biology and structure is needed.  To begin with, a cell is the most fundamental 
biological unit. The basic parts of an animal cell commonly referenced in stem cell research 
include the cell membrane, nucleus, chromosomes, and DNA (Figure-1).  
 
 
Figure-1:  Fundamental Diagram of a Cell.  The cytoplasm (yellow) is 
enclosed by a cell membrane (outer black line).  The nucleus (green) 
contains chromosomes (red) that contain DNA.  (Terry, 2000) 
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The cell membrane is the outer barrier of a cell. The nucleus acts as the “brain” of the 
cell.  It contains chromosomes composed of DNA.  This DNA codes for specific proteins that 
provide the genetic identity of the cell. As a result, the nucleus directs the function of the cell. 
Two different types of cell division, meiosis and mitosis, distinguish respectively germ cells 
(sperm and egg cells) from somatic cells (any cells in the human body other than germ cells). 
Somatic cells are used in the genetic reprogramming techniques for iPS stem cells. Germ cells 
are primarily used for the creation of embryonic stem cells (Scott, 2006). 
 
Stemness and Stem Cell Potentials 
Before discussing the various types of stem cells, a basic knowledge of “stemness”, “the 
idiosyncrasies that make stem cells stand out from a crowd of millions” is necessary (Scott, 
2006).  Stemness is determined through two primary characteristics, potency and asymmetric cell 
division (Figure-2).  The totipotent stage (diagram upper center) occurs in a newly fertilized egg 
through cells that accumulate during the egg’s first few cell divisions. Totipotent stem cells are 
the most powerful as they can become any cell or tissue in the body, or they can produce extra-
embryonic tissue such as the placenta.  After a few days of dividing, these totipotent cells have 
differentiated further to become a blastocyst, a hollow ball of cells. The outer germ layers of the 
blastocyst have the potential to form the placenta while the inner cell mass (ICM) of the 
blastocyst has the ability to make an embryo.  The ICM cells are embryonic stem cells, and they 
are pluripotent (diagram center). They can become most but not all cell types as they cannot 
form tissues for fetal development (such as the placenta).  Pluripotent cells differentiate further 
to produce multipotent stem cells (diagram lower left).  These cells can produce several types of 
related cells, such as the ability of hematopoietic stem cells to produce all the cellular 
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components of blood.  These cells differentiate further to produce unipotent stem cells,that have 
the ability to form one type of tissue (Scott, 2006).  Adult stem cells are either multipotent or 
unipotent cells.  Current research is focused on whether adult stem cells have the ability to 
differentiate into other types of cells than the tissue from which they are isolated, a process 
termed plasticity (“Origin”, 2010).  It is currently debated whether adult stem cells exhibit 
plasticity, however, “…the number of research papers reporting plasticity outnumbers papers 
that dispute it by 10 to 1” (Scott, 2006). 
 
Figure-2:  Diagram of Stem Cell Asymmetric Divisions and Potentials.  
Rotational arrows denote the production of new stem cells, while straight arrows 
represent differentiation to lower potential cells. (“Origin”, 2010) 
 
Cell division is another quality that determines stemness. Stem cells exhibit a distinctive 
type of cell division. Stem cell division, unlike normal cell division does not follow the “exact 
copy” rules of mitotic division (Scott, 2006).  When stem cells divide, they produce one 
undifferentiated cell (to replenish the stem cell population) while also producing one 
differentiated cell.  Thus, stem cells have a hybrid cell division that both replenishes the 
population of stem cells and creates daughter cells with specialized abilities (Scott, 2006).  As a 
result, stem cells both self renew and go through asymmetric cell division.  
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Embryonic Stem Cells 
Embryonic stem (ES) cells in animals were first documented in the 1950’s by 
embryologist Leroy Stevens, who at the time worked at Jackson Laboratories in Bar Harbor, 
Maine.  His discovery came as a result of curiosity and chance. One day Stevens came across a 
mouse with an odd gate. This animal had developed a large tumor on its testes. Stevens dissected 
the tumor and discovered that it contained a hodgepodge of mouse parts including “skin, teeth, 
bone, tangles of hair, and marts of muscle” (Scott, 2006). This strange tumor resulted from a 
benign form of cancer called a teratoma.  Stevens transplanted bits of the tumor into the bodies 
of healthy mice and discovered that they also grew a multitude of cell and tissue types.  With 
some of the fully differentiated cells in the tumor Stevens noticed a uniform group with the 
ability to replicate themselves. He believed that these cells were the reason for the array of 
mouse parts in the teratoma. With this hypothesis in mind, Steven’s and his lab attempted to 
isolate and culture strains of these “stem cells”.   
In the 1960’s, other labs learned to culture these “stem cells” that they called embryonal 
carcinoma cells (Scott, 2006).  As time progressed, scientists also found methods to keep these 
cells alive for longer periods of time by periodically changing the medium (a solution composed 
of sugar, salts, and a variety of extracellular matrix proteins).  In this medium, the cultured cells 
divided into new populations of cells (Chamany, 2004).  This environment kept the cells from 
differentiating.  It was also observed that “…the tumor cells showed amazing flexibility” (Scott, 
2006).  Indeed they were able to change into a multitude of tissue types when different chemicals 
and substances were added to the media, “…even cardiac cells appeared, twitching with a 
spontaneous heartbeat” (Scott, 2006).  In 1981, Gail Martin was able to derive a pluripotent cell 
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line (ES cells) from mouse embryos prepared by in vitro fertilization (IVF), and cultured in 
conditioned medium from teratocarcinoma cells (Martin, 1981).   
Using this murine ES cell research as a basis, primate, and later human, embryonic stem 
cell lines were produced.  The first tangible creation of human embryonic stem cell lines did not 
occur until 1998 when James Thomson from Wisconsin University created an ES cell line from 
human IVF embryos (Thomson et al., 1998).  This advancement remains central to the stem cell 
controversy lingering in society today.  The isolation process begins with the in vitro fertilization 
of sperm and egg from human donors to reproductive clinics.  This newly fertilized egg is 
totipotent, meaning if it is allowed to grow it can develop into a fetus and the extra-embryonic 
tissue such as the placenta.  After 4-5 days of cell division, a hollow ball of cells termed a 
blastocyst is formed (Figure-3).  
 
 
Figure-3:  Diagram Showing the Two Main 
Methods for Isolating Human ES Cells.  
Sperm and egg are united during in vitro 
fertilization (upper left).  The zygote is cultured 
4-5 days to the blastocyst stage (upper center).  
The inner cell mass cells can be isolated 
(diagram center) to produce ES cells (diagram 
lower).  Alternatively, germ cells can be isolated 
from an aborted fetus (diagram right) to obtain 
ES cells.  (Origin, 2010) 
 
 
 
 In the blastocyst, the outer layer of cells will eventually form the placenta, while the 
inner cluster of cells (inner cell mass) will eventually form the fetus (Scott, 2006).  The cells of 
the inner cell mass are pluripotent.  This means that they can dedifferentiate into over 220 tissue 
cell types in the body, but not all types necessary for fetal development (Furcht and Hoffman, 
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2008).  Some of these formed cell types include liver cells, epithelial cells, nerve cells, muscle 
cells, and white blood cells (Espejo, 2002).  It is the ability of ES cells to divide, while also being 
able to differentiate into many different tissues, that creates their medical potential to regenerate 
cells in damaged organs.  Since ES cells are not totipotent, if inserted into a woman’s uterus, 
they would not create a fetus.  However, the removal of the inner cell mass from the blastocyst to 
obtain the ES cells usually destroys the embryo, and the embryo if implanted could have created 
a fetus.  Thus the ethical dilemma is does the potential ability of ES cells to save human lives 
outweigh the “death” or potential life of the embryo (Scott, 2006)? 
At about the same time that Thomson was creating his first human ES cell lines using 
IVF blastocysts, John Gearhart discovered that ES cells can also be obtained using fetal tissue 
from germ cells (Shamblott et al., 1999).  Despite using different methods, both Gearhart and 
Thomson managed to create strong long-lived ES cell lines. These lines, and others derived 
subsequently, are integral to the medical community for ongoing experimentation in biological 
cures (Chamany, 2004).  
ES cells provide the comparative basis through which all other stem cell types are 
compared.  One test for ES cell pluripotency, teratoma formation, involves transplanting 
potential stem cell lines into an adult animal. If a teratoma forms containing all three germ layers 
differentiated from the original cells, then the ES cells are pluripotent. Another indicator of all 
long lived stem cells is the presence of the enzyme telomerase.  In humans, only stem cells and 
germ cells appear to have telomerase. This is an intriguing fact since this protein is also 
expressed by long lived cancer cells and helps them grow out of control (Scott, 2006).  A deeper 
understanding of the function of telomerase in stem cells will hopefully provide scientists with 
the knowledge to aid them in their efforts to cure cancers.  
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Parthenogenetic Stem Cells 
In 1912, Jacques Loeb first documented artificial parthenogenesis. By placing sea urchin 
eggs in various concentrations of salt, he stimulated the cells to divide without fertilization, 
forming an embryo as if they were fertilized. This experiment suggested that a sea urchin egg 
cell has enough plasticity to create all the cells in a developing embryo (Chamany, 2004).  
Although some amphibians, especially bees and ants, naturally reproduce using parthenogenesis, 
in animal cells parthenogenesis does not occur in nature.  The first published account of 
producing human parthenote embryos occurred in 2001 (Cibelli et al., 2001), however the eggs 
only divided a few times, and did not produce blastocysts from which ES cells could be obtained.  
In 2003, the human parthenote embryos survived long enough to produce blastocysts from which 
ES cells were obtained (Westphal, 2003).   Then in 2007, unpublished claims surfaced of the 
establishment of the world’s first human ES cell lines from parthenogenesis (Brevini and 
Gandolfi, 2007).   Due to the fact that fertilized embryos are not destroyed to obtain these ES 
cells, some scientists argue this process is less ethically controversial, and may produce an 
alternative source of ES cells (Westphal, 2003). 
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Induced Pluripotent Stem Cells 
Across the ocean, in 2006 Shinya Yamanaka’s team at Kyoto University in Japan 
generated a technique to create the world’s first induced pluripotent stem (iPS) human cell line 
(reviewed by Vogel, 2006; first published by Takahashi et al., 2007).  Although iPS cells 
represent the newest member of the stem cell community, they appear to have powerful ES-like 
differentiation potential while no embryo is destroyed to obtain them.  These cells are created 
through the deliberate introduction of nucleic acids encoding stem cell-associated proteins into 
adult differentiated somatic cells, commonly skin fibroblast cells (“Induced,” 2010).  The 
extreme scientific excitement of this success results from the fact that if the iPS cell line is 
induced from a patient’s own skin fibroblasts, the iPS cells would be genetically identical to the 
patient, so likely would not be rejected by the patient’s immune system.  And moreover, the 
technique does not destroy an embryo. 
The initial 2006 experiment used viruses to introduce four genes (OCT3/4, SOX2, KLF4, 
and c-MYC).  After culturing these genetically altered cells for several weeks, colonies of cells 
with properties resembling those found in human ES cells were observed.  Indeed these 
populations of cells contained telomerase, and doubled at approximately the same rate as ES 
cells. The behavior of these human iPS cells indicates that by introducing particular genes into a 
skin fibroblast cell, the differentiated cell can be reprogrammed, resulting in the activation of 
pluripotency genes and the silencing of normal operating fibroblast genes. Yamanaka and his 
team continued their research to discover that the iPS cells could be “differentiated to make 
beating heart muscle, and proteins characteristic of neurons”, and could also form cells from the 
three major germ layers (ectoderm, mesoderm, and endoderm) (Baker, 2007). 
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At the University of Wisconsin, James Thomson and Junying Yu made similar 
experiments in their attempts to genetically alter neonatal fibroblast cells so that they mimicked 
the function of ES cells. Their team also used four genes, but two of their genes differed from 
those used in Yamanaka’s experiments. Instead of KLF4 and c-MYC, Thomson’s group used 
NANOG and LIN28.   Thomson and Yu found that “from 600,000 neonatal cells, 57 iPS cell 
colonies were generated with properties similar to ES cells” (Baker, 2007).  From those 57 
colonies, four lines of iPS cells were cultured. These cells expressed surface proteins like those 
found in ES cells, and like Yamanka’s team’s the cells were capable of forming a teratoma 
containing all three embryonic germ layers. 
Eventually, the induction technique was modified to require only two genes, and did not 
require the genes to be delivered by viruses.  One group also succeeded by transfecting the 
transcription factor proteins encoded by the genes instead of using the genes themselves. 
Although iPS cells appear to solve the ethical dilema of embryo destruction, 
unfortunately they appear to have some problems.  iPS cell experiments done in mice indicate 
that mice treated with iPS cells may be prone to tumors. But luckily, Yamanaka published a 
subsequent paper in Nature Biotechnology showing that both human and mouse adult fibroblasts 
could be reprogrammed using a gene combination without cMYC (which tends to cause tumors).  
The genetic reprogramming took a week longer to occur, but produced no detectable tumors.  As 
iPS cells have been shown to form some tissues but not all, some scientists worry that iPS cells 
are not truly pluripotent. However, future research should help answer that question. Thus, 
although more studies are necessary, iPS cells hold great potential for advancements in the 
medical field by providing an easily-attainable, potent stem cell line for experimentation (Baker, 
2007).   
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Adult Stem Cells 
Adult stem cells (ASCs) are isolated from adult tissues.  Their main function in the body 
is to replace dead or injured cells with new ones that function appropriately (Adult, 2006).  ASCs 
exist throughout our bodies “from head to toe” (Scott, 2006), but are most commonly found in 
parts of the body such as bone marrow, umbilical cord blood, intestine, skin, and amniotic fluid 
(Furcht and Hoffman, 2008).  Though natural in origin, ASCs have more limited applications in 
comparison to other stem cell types as they are unipotent and multipotent, as opposed to 
pluripotent (Espejo, 2002).  However, special varieties of ASCs have displayed plasticity and can 
form many types of tissue, including some outside of the narrow region of the body in which 
they exist.  For example, hematopoietic stem cells (HSC’s) taken from the blood and marrow are 
an excellent example of stem cells that exhibit plasticity as they can form nine kinds of blood 
cells, including red blood cells, B lymphocytes, T lymphocytes, natural killer cells, neutrophils, 
basophils, and macrophages (Bethesda, 2009), and HSCs have been shown to be capable of 
differentiating into neuronal cells when treated with appropriate growth factors (Scott, 2006).  
 Unfortunately, ASCs are far more difficult to isolate than ES cells.  The cells are rare in 
the body and they are surrounded by a vast majority of differentiated cells.  Moreover, ASCs 
have a close relationship with intermediate transitory cells that they produce, making it difficult 
to tell them apart.  This makes their identification far more difficult than identifying ES cells 
from a blastocyst.  However, the progenitor cells divide a limited number of times while adult 
stem cells can divide indefinitely, so if the cell does not self replicate, it is not a stem cell (Scott, 
2006).   
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How scientists distinguish between different types of adult stem cells is a bit trickier. 
Theoretically, each cell type has a distinct genetic signature, even if we have not yet deduced 
what it is. One identifying marker is the expression of specific proteins on the outer layer of the 
cell (known as antigens). Each cell variety expresses diverse antigen types and combinations. For 
example, blood cells have surface markers called CD45 (Scott, 2006).  It is through the 
expression of such surface antigens that researchers are able to differentiate between adult stem 
cells such as mesenchymal stem cells and say neural stem cells. Mesenchymal stem cells can 
create bone, muscle, cartilage, fat, and other connective tissue (Bethesda, 2009), while neural 
stem cells found in the brain can form nerve cells, neurons, and two types of non-neuronal cells, 
astrocytes and oligodendrocytes (Bethesda, 2009).  Both of these adult stem cell types hold many 
possibilities for medicine in the future. 
With respect to using ASCs for medical applications instead of ES cells, they have less 
medical potential (they can only differentiate into limited cell types), they are harder to isolate 
(as discussed above), and most types are harder to grow in large quantities.  Current research is 
focused on trying to solve these problems to avoid having to use ES cells for medical 
applications if possible. 
 
Chapter-1 Conclusion 
Overall, it is evident from our discussion so far that stem cells do not come from a single 
source.  In the case of embryonic stem cells, they come from the inner cell mass of a blastocyst. 
iPS cells come from adult fibroblast cells that have been genetically engineered to function as 
pluripotent cells. Parthenogenic ES cells are created through the chemical treatment of 
unfertilized eggs that trick an egg cell into thinking it has been fertilized. Adult stem cells reside 
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in various locations throughout our body, but are hard to isolate and grow.  Stem cell research 
has been around since the 1800’s, so stem cells are not new to the scientific community. 
However, the possible application of stem cells to 21
st
 century regenerative medicine makes 
them both intriguing and crucial to understand in the modern world.  
 
Chapter-1 Bibliography 
 
Adult Stem Cells (2006) Brown University.   
http://www.brown.edu/Courses/BI0032/adltstem/asc.htm 
 
Baker, Monya (2007) "Adult Cells Reprogrammed to Pluripotency, without Tumors”.  Nature 
 Reports Stem Cells. Nature Publishing Group : Science Journals, Jobs, and Information.  
 06 Dec. 2007.  Web. 08 June 2010.  
 http://www.nature.com/stemcells/2007/0712/071206/full/stemcells.2007.124.html 
 
Bethesda (2009) "What Are Adult Stem Cells?" NIH Stem Cell Information Home Page.  
 21 Apr. 2009. Web. 09 June 2010.  
 http://stemcells.nih.gov/info/basics/basics4.asp 
 
Brevini X, and F Gandolfi (2007) Parthenotes as a Source of Embryonic Stem Cells. Cell 
Proliferation.   http://www.blackwell-synergy.com/doi/pdf/10.1111/j.1365-
2184.2008.00485.x 
 
Chamany K (2004) Stem Cell Primer.  
http://www.garlandscience.com/textbooks/cbl/pdflibrary/stemcells_primer.pdf 
 
Cibelli JB, Kiessling AA, Cunniff K, Richards C, Lanza RP, West MD (2001) Somatic Cell 
 Nuclear Transfer in Humans: Pronuclear and Early Embryonic Development.  Journal of 
 Regenerative Medicine 2: 25-31.   
 
Espejo, Roman (2002) Human Embryo Experimentation. San Diego, CA: Greenhaven, Print. 
 
Furcht, Leo, and William R. Hoffman (2008) The Stem Cell Dilemma: Beacons of Hope or 
 Harbingers of Doom?  New York: Arcade Pub., Print. 
 
"Induced Pluripotent Stem Cell" (2010) Wikipedia, the Free Encyclopedia. Web. 09 June 2010.  
http://en.wikipedia.org/wiki/Induced_pluripotent_stem_cell 
 
Martin, Gail (1981) Isolation of a pluripotent cell line from early mouse embryos cultured in 
 medium conditioned by teratocarcinoma stem cells.  Proc Natl Acad Sci USA, 78(12): 
 7634-7638.   
 
 17 
"Origin of Stem Cells" (2010) Welcome to the World of Stem Cells. Web. 08 June 2010.  
http://stemcellworld.tripod.com/page3.html 
 
Scott, Christopher T. (2006) Stem Cell Now: From the Experiment That Shook the World 
 to the New Politics of Life.  New York:  Pi Print. 
 
Shamblott MJ, Axelman J, Wang S, Bugg EM, Littlefield JW, Donovan PJ, Blumenthal PD, 
Huggins GR, Gearhart JD (1999) Derivation of Pleuripotent Stem Cells From Cultured 
Human Primordial Germ Cells.  Proc Natl Acad Sci USA  95: 13726-13731. 
 
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) 
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors.  
Cell 131: 1-12.   
 
Terry, Thomas (2000) "MCB 229 Spring 2000: Introduction to Microbiology." UNI HH Fkt 6.1  
 Biologie.  06 Jan. 2000.  Web. 08 June 2010.   http://www.biologie.uni-hamburg.de/b-
online/library/micro229/terry/229sp00/lectures/intro.html 
 
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM 
 (1998) Embryonic Stem Cell Lines Derived From Human Blastocysts.  Science  282: 
 1145-1147. 
 
Vogel G (2006) Four Genes Confer Embryonic Potential.  July 7.  Science 313: 27. 
 
Westphal, Sylvia (2003) 'Virgin Birth' Method Promises Ethical Stem Cells. Newscientist.       
http://www.newscientist.com/article/dn3654-virgin-birth-method-promises-ethical-stem-
cells.html.   
 
 
 18 
CHAPTER-2:  STEM CELL APPLICATIONS 
 
As discussed in Chapter-1, scientists have discovered multiple types of stem cells, but 
what makes them worth the moral, mental, and physical effort?  This chapter is designed to 
discuss their worth, various ways in which stem cells can be applied.  Stem cell therapy involves 
replacing cell loss and inducing the body’s repair mechanisms to treat some types of disorders 
(Levesque, 2005).  In this chapter, possible stem cell therapies for treating patients with 
Parkinson’s Disease, severe burns, cancer, kidney transplants, and spinal cord injuries will be 
discussed.  In some cases, most of what we know results from experiments on animal models, 
while in other cases stem cells are being used on human patients. 
 
Stem Cells and Parkinson’s Disease 
Parkinson's disease (PD) is a disease of the central nervous system that affects an area of 
cells in the middle of the brain called the substantia nigra. These brain cells slowly begin to lose 
the ability to produce dopamine, a neurotransmitter involved in neuromuscular control.  The 
symptoms of PD vary from individual to individual, however common symptoms include 
difficulty keeping balance, shaking of the hands, arms and legs, and feelings of anxiety or 
depression (“Our Outstanding…,” 2010).  More than four million elderly people around the 
world are affected by Parkinson’s disease.  One million of those affected reside in North 
America (“Our Outstanding…,” 2010).  The causes of PD are unclear, and there is no current 
preventative cure for Parkinson’s disease. Current therapies involve using drugs to mimic 
dopamine or its precursors, but these treatments have only short lasting effects and often lose 
their efficacy over time.  However, the use of stem cells in certain procedures to regrow 
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dopaminergic nerve cells seems to bring hope to the community of individuals affected by 
Parkinson’s disease.  
At the Parkinson's Clinical Center in Beijing led by the head neurologists Dr. Like Wu 
and Dr. Xiaojuan Wang, 157 PD patients between the ages of 41 and 86 have been treated with 
fetal neural stem cells or hematopoietic stem cells from bone marrow or umbilical cord blood, 
and 91% showed significant improvements (“Our Outstanding…,” 2010). Dr. Wu and Dr. Wang 
use a gene-targeted stem cell transplantation procedure via a subarachnoid lumbar puncture.  For 
the lumbar puncture, a needle is inserted into the spinal canal in the lower back and a small 
amount of cerebral spinal fluid is taken. This fluid is then mixed with neural stem cells collected 
from fetuses, or hematopoietic stem cells collected from bone marrow or umbilical cord blood, 
then injected into the lumbar in four separate injections. The stem cells take six to seven hours to 
circulate per injection. The circulating stem cells flow through the cerebral spinal fluid in the 
lumbar and into the brain, where they sometimes grow into neurons to repair the damaged neural 
system and improve the degenerated neuromuscular state of the patients.  For this procedure, 
medication is also given in order “…to adjust the immune function, provide neural nourishment 
and clear the internal microenvironment to protect the neurons and help the future growth of 
injected stem cells” (“Our Unique…,” 2010).  Thus, at this center, stem cells appear to offer 
hope where traditional medication cannot.  However, this Chinese center’s promising results 
have not yet been published in reputable refereed scientific journals, so it is difficult to judge the 
quality and reproducibility of the work. 
With respect to human PD stem cell reports published in the refereed literature, several 
labs have reported success with fetal tissue transplants (containing neural stem cells) (Madrazo et 
al., 1988; Lindvall et al., 1989; Freed et al., 2001, Mendez et al., 2002).  And some success has 
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been reported with adult olfactory mucosal stem cells (Levesque, 2005).  Currently, embryonic 
stem cells have not been used to treat human PD patients, but human ES cells have been shown 
to be able to differentiate into dopamine-producing cells (Perrier et al., 2004).  
 
Epithelial Tissues Engineered from hES derived Keratinocytes 
In the United States, approximately 2.4 million burn injuries are reported each year. Of 
those hospitalized, 20,000 have major burns involving at least 25% of their total body surface 
(“Burn”, 1992). Skin, one of the most important organs in our body due to its ability to protect us 
from desiccation and harm, is commonly in short supply within medical facilities. Currently, 
there are already processes for the production of autologous epidermis tissues in the lab, however 
these tissues, made from the patient’s own keratinocytes, take at least 3 weeks to culture.  
Allografts from cadaver skin can sometimes be used as a temporary cover for full thickness 
burns, or semisynthetic products using bovine collagen or allergenic fibroblasts can be functional 
as well, but these contain adult cells which commonly induce an immune rejection called graft 
versus host disease (GHVD).  Thus, there is a need for an autologous epidermal tissue that 
avoids immune rejection and is easily accessible (Guenou, 2009). 
Keratinocytes derived from human embryonic stem cells (K-hESC’s) can form an 
epithelium (skin layer) with multiple levels that resembles the normal outer layers of human 
skin, both in cell culture (in vitro) and through the application of these grafts on the body (in 
vivo).  The culture of this tissue-engineered skin is produced using a co-culture of hESCs with 
feeder cells over 40 days.  The feeder cells temporarily support the stem cells in culture until the 
cells have divided enough to support themselves. BMP4 (a growth factor) is also used in the 
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culture medium to stimulate the hESCs in the preliminary steps of differentiation to grow in a 
flat, tissue-like pattern.  
This hESC approach could provide an unlimited source of temporary skin replacement 
for patients with extensive burns waiting for autologous grafts (Guenou et al., 2009).  Because 
the ES cell line is immortal, issues with accessibility would be eliminated. Moreover, due to their 
early developmental stages, “K-hESCs express little major histocompatibility complex (MHC), 
so should produce less graft-versus-host disease (Guenou et al., 2009).  K-hESCs also produce 
certain components that form an epidermal-dermal junction in the body, which is important for 
integrating the foreign tissue in the body.  Though more extended clinical trials are necessary to 
determine whether this tissue will truly function effectively, K-hESC-engineered epithelium 
appears to be a promising, new medical tool for burn victims. 
 
Treatment of Cancer with hESC Derived NK Cells 
Cancer kills one of four individuals on Earth (Scott, 2006).  Possibly the greatest hot spot 
for stem cell research is oncology.  Researchers have experimented with multiple techniques in 
their search for a cancer cure, but cancer is a tricky, versatile, and prominent enemy.  Luckily, 
with stem cell therapy there appears to be hope for the future.  
Multiple cell-based remedies using hematopoietic stem cell (HSC) transplantation and T 
cell immunotherapy for malignant tumors are already in clinical practice.  In fact, the use of 
HSCs from bone marrow to treat leukemia has been in use for over 50 years (since 1959) with 
about 40,000 bone marrow transplants performed annually worldwide (Horowitz, 1999).  Thus, 
HSCs remain the most characterized of all the types of stem cells. 
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Some tumors disrupt antigen presentation which allows them to avoid being recognized 
by our T-cell-mediated immune response.  The inability of tumor cells to activate an effective 
antitumor immune response allows the cancer to persist within the body.  But luckily, T-cells are 
not the only immune response in our body.  Natural killer (NK) cells are an integral part of our 
antitumor immunity.  These cells recognize and lyse cells in our body not presenting MHC on 
their surface, so if cancer cells present no MHC due to antigen presentation disruption, they can 
be lysed by NK cells.   
CD56+ and CD45+ NK cells can be derived from human embryonic stem cells (Woll et 
al., 2009).  In recent studies, hESC-derived NK cells have removed established human tumors in 
immune-deficient mice. The testing that took place involved using tumor inoculated mice. These 
mice were divided into three groups. One control group received no NK-cell infusion. The 
second group was given systematic infusions of 2x10
6
 NK cells derived from hESCs, and the 
third group was given periodic shots of 2x10
6
 NK cells derived from umbilical cord blood.  After 
three weeks, eighteen out of the twenty mice that did not receive any NK cell treatment 
developed large tumors. All of the mice treated with hESC-NK cells demonstrated clearance of 
the primary tumor in 2 weeks, and 5 of 13 mice treated with UCB-NK cells were tumor-free.  
Through bioluminescent imaging at 8 weeks, no evidence of tumor recurrence was observed in 
the hESC and UCB-NK mice (Woll et al., 2009).  Thus, hESC-NK cells and UCB-NK cells are 
efficient at removing human tumor cells and preventing their growth in mice. In addition, this 
study proved that hESC-NK cells are more proficient at clearing tumors than UCB-NK cells 
(Woll et al., 2009).  
However, there are some drawbacks to using NK cell procedures, as “NK cells are 
limited to specific cancer types [especially those not presenting MHC on their surface], and not 
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all patients demonstrate an optimal response” (Woll et al., 2009).  Similarly, since only the H9 
human embryonic stem cell line was used in these experiments, studies on whether the other hES 
cell lines behave in the same manner needs to be completed.  In addition, NK clinical trials on 
human patients need to be started to see if hESC NK cells can clear cancers in the human body.  
 
Using Mouse ESCs to Predict Future Cancer Risk 
Stem cells have also proven helpful in identifying who may be at risk for getting cancer 
in the future.  In fact, the National Cancer Institute has developed a new test for breast cancer 
called a functional assay. This test was initially created using mouse ES cells, and it evaluates 
mutations in a gene known to increase breast cancer risk in women. Proteins produced by 
BRCA1 (breast cancer gene 1) and BRCA2 (breast cancer gene 2) function as tumor suppressors. 
Genetic defects in these tumor suppressors cause an increased risk of breast or ovarian cancer in 
these individuals.  Indeed, “studies have shown that a woman who has a mutation in one of these 
genes has a 35-85% risk of developing breast cancer by age 70, compared to the average 
American woman’s lifetime risk of 12.3%” (Sharan, 2008).  As a result, many women undergo 
genetic testing to determine if they are at risk, and if so should plan ahead with their physicians.   
This new functional assay helps scientists evaluate the effects of less common mutations 
in the BRCA2 gene through using mouse embryonic stem cells. Functionally normal human 
BRCA2 gene variations (mutations that would not cause cancer so would be of no concern) will 
compensate for mouse BRCA2 deficiency in BRCA2-deficient mouse embryonic stem cells. 
Since mouse BRCA2 is necessary for the survival of mouse embryonic stem cells, if the human 
variation of the BRCA2 gene being tested does not function properly to supply BRCA2 for the 
BRCA2-deficient mouse stem cells, the cells will die, and the genetic variation is of clinical 
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concern.  It has been found that “if a sequence variation does not alter the function of BRCA2, 
the risk of developing cancer is probably the same as that of the rest of the population, but if the 
genetic change is disruptive, the risk of developing cancer increases significantly” (Sharan, 
2008).   
Research is also being performed to see if functional assays for BRCA1 are possible, as 
there are over 1,900 known BRCA1 and BRCA2 variations.  Many of these variations are 
uncommon and thus their functional effects, without testing, are unknown. Without functional 
assays, scientists are limited to determining the effects of BRCA1 and BRCA2 alterations 
through segregation analysis, a process that analyzes genetic alterations in families with high risk 
cancer patterns. This process is effective, but it only provides data for a small portion of the 
1,900 known BRCA1 and BRCA2 variations found in our population. 
Overall, BRCA2 testing, using mouse embryonic stem cells in vitro, seems to be a 
promising method for the detection of harmful mutations of the BRCA2 gene.  So far, 17 
variants have been tested by this functional assay at a rate of “three to five gene variants every 
two to three months” (Sharan, 2008). However, FDA approval for the use of this functional assay 
in a clinical setting is still necessary before it can be used for diagnostic testing. 
 
Kidney Transplants: Using Adult Blood Stem Cells to Create a Mixed Chimera 
 Although bone marrow and organ transplants are relatively common procedures in the 
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st
 century, the results are far from perfect.  For example, kidney transplant patients have to take 
approximately 30 different immunosuppressive drugs daily to prevent their body’s rejection of 
their genetically foreign kidney. These drugs compromise the immune system and increase the 
risk for heart disease, diabetes, and cancers. Additionally, studies have found that in 
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approximately 10 to 15 years, the transplanted kidney would likely be rejected and another 
kidney transplant would be needed (Fox, 2007).  
Luckily, a new technique for kidney transplants has been created using embryonic stem 
cells. This technique involves giving the patient both a new kidney transplant and a new immune 
system created from the kidney donor’s adult blood stem cells. This new immune system, which 
works in conjunction with the original immune system of the patient, prevents the kidney 
transplant patient’s body from rejecting the kidney and eliminates the need for immuno-
suppressive drugs that prevent graft versus host disease (GVHD).  GVHD is a common 
complication of allogeneic bone marrow and organ transplants where the donor cells attack the 
patient's organs and tissues (“Graft vs Host Disease”, 2010).  
The simple theory behind this procedure is that by pre-treating the patient with donor 
hematopoietic stem cells (HSCs) tolerance to the transplanted kidney cells can be induced.  In a 
more thorough explanation, our immune system identifies foreign cells through the expression of 
human leukocyte antigens (HLAs).  HLAs are present in allogeneic organ and bone marrow 
transplants. As a result, in order to get a human body to accept a foreign kidney, a mixed 
chimerism that creates a duel immune system must be formed. This new process involves giving 
immunosuppressant drugs such as cyclosphosphamide, and partially irradiating the patient’s 
thymus.  Then a same-donor bone marrow transplant is completed followed by the donor kidney 
transplant.  In doing so, the T cells of the donor and the host are kept at bay which allows the 
donor and host stem cells to learn to accept each other. Once the donor and host stem cells 
establish their peace, a duel immune system is created. When this process is completed, the 
patient can stop taking immunosuppressant drugs.   
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In preliminary animal testing at the Massachusetts General Hospital, “the approach 
created a mixed chimerism and total graft acceptance with immunosuppressives in 100 percent 
of the mice” (Fox, 2010).   In humans, in 1998, Dr. David Sachs from the Massachusetts General 
Hospital was the first to treat a human patient, a kidney failure/cancer patient. Surprisingly the 
patient not only accepted their new kidney, but the mixed chimerism caused their cancer to go 
into remission. Five other kidney failure/cancer patients were then treated with this procedure in 
addition to three kidney failure-only patients. Eight out of nine accepted their kidneys and are 
completely without immunosuppressives. Only one patient suffered the rejection of their kidney 
(Fox, 2010).  
Further advances in the world of bone marrow and organ transplantation are being 
investigated at Harvard by a man named Gorge Daley.  Daley is working on creating 
hematopoietic stem cells (HSCs) from human embryonic stem cells that would produce human 
chimeras with organs and blood made entirely form embryonic cells. Though he is still in the 
preliminary stages of his research, his idea shows great promise for the medical community. As 
he wrote in a 2003 paper on experimental hematology, “…an important role for ES-derived HSC 
may be the ability to induce hematopoietic chimerism in individuals undergoing transplants with 
other types of ES-derived tissues.  This chimeric effect would enable a large patient population 
to access cellular therapies from a limited bank of approved ES cell lines” (Fox, 2007). 
 
Spinal Cord Injuries 
Another promising use for stem cells is in the repair of spinal cord injuries. The use of 
stem cells to treat animal models of spinal cord injuries first occurred in 1999 with the use of 
embryonic stem cells (McDonald et al., 1999), and has since been tested with human ES cells 
 27 
(Kerr et al., 2003).  Many different types of cells including neurons are destroyed during spinal 
cord injuries.  In a numerous accident cases, the cord is not broken and some of the neuronal 
axons that carry signals from the body to the brain remain intact.  But these axons have lost their 
ability to transport messages due to the loss of oligodendrocytes of which the axon’s insulating 
myelin sheath is composed. Lack of this myelin sheath causes paralysis. Scientists have used 
hESCs to make mixed cultures that contain oligodendrocytes. When chemically-demyelated rats 
were given shots of this stem cell mixture, they regained a fractional improvement in the use of 
their hind limbs in comparison to ungrafted mice (Panchision, 2006). In another experiment at 
the Krembil Neuroscience Center at the Toronto Western Research Institute and the University 
of Toronto, Michael Fehlings and his team used cells from the brains of adult mice and 
transplanted them into rats with damaged spines. When transplanted a maximum of two weeks 
after the injury, supplemented with various growth factors and immune-suppressing drugs, 
“more than one-third of the transplanted cells traveled along the spinal cord, were incorporated 
into damaged tissue, developed into the type of cell destroyed at the injured site, and produced 
myelin” (“Stem Cell…,” 2006). 
More recently, bone marrow mesenchymal stem cells (BMSCs) have been shown to 
increase the healing of injured spinal cords in animal models (Gu, 2009).  In an experiment 
injecting 3x10
5
 BMSCs into one group of injured mice, and a placebo injection into the control 
group of mice, at 8 weeks there was an increase in the reduction of the cavity caused by the 
spinal cord injury in the BMSC injected mice in comparison to the control. A transmission 
electron microscopic examination displayed that there was also a greater number of axons in 
BMSC rats than in the control. Moreover, a coculture system displayed that “The length and the 
number of neuritis from spinal neurons significantly increased when they co-cultured with 
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BMSCs” (Gu, 2009). As a result it appears that BMSCs promotes the regrowth of injured spinal 
cords and decreases the wound’s volume.   
 
Chapter-2 Conclusion 
Stem cells with their functional powerhouse of tissue regeneration and medical 
possibilities provide a means through which many incurable diseases like cancer or severe 
wounds such as spinal cord injuries may be reduced or cured.  Thus far, in most cases, stem cell 
studies using animal models have successfully been completed.  These animal tests are 
imperative as such tests must be done in advance of human testing, and is many cases animal 
data remains our only source of information.   
However, it is not true that no human data exists on stem cell applications.  In the U.S., 
studies on the safety and efficiency of stem cell therapies on human patients occur more 
frequently than many believe. In areas such as China, clinics for stem cell therapies for 
Parkinson’s Disease have begun to treat previously incurable patients, but their data have not yet 
been evaluated in the refereed scientific literature.  Although hematopoietic stem cells have been 
used for over 50 years to treat leukemia, for other stem cell applications it is hard to determine 
whether the therapies will live up to their predicted potential.  But through progress in stem cell 
cancer treatment techniques, the alleviation of Parkinson’s disease symptoms, the creation of 
organs such as skin for the treatment of burns, the creation of mixed chimerism for kidney 
transplants, and the advanced repair rate in spinal cord injuries, the possible medical applications 
of stem cells appear to be both exciting and promising.  
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CHAPTER-3:  STEM CELL ETHICS 
 
“Suppose a fire broke out in a fertility clinic, and you only had enough time to save either 
a five-year-old girl or a tray of twenty frozen embryos. Would it be wrong to save the girl?” 
(Sandel, 2007) This type of ethical question encompasses the main debate surrounding stem cell 
research, namely to what extent should an embryo be treated as a human being.  In this chapter, 
the discussion of stem cell ethics goes beyond the technology to converse about whether stem 
cell research is more of a benefit or detriment to society, and whether this research should 
continue.  
The benefits of stem cell research vary depending upon the type of stem cell under 
discussion.  Some cells such as iPS cells are extremely new, and have not yet been used to save 
any lives.  Other cells such as adult stem cells (ASCs) and embryonic stem (ES) cells are well 
established, and have already been used in successful clinical applications. However, both adult 
stem cells and iPS cells are not obtained through the “killing” of an embryo whereas embryonic 
stem cells are.  As a result, the usage of ES cells is a popular debate in America and around the 
world, focusing on whether the ability of ES cells to medically save lives outweighs destroying 
an embryo to obtain them. Ultimately this debate revolves around the question of when life 
begins; an individual’s conclusion on this topic affects their stance on whether destroying an 
embryo is murder.  
Even within the scientific community, the answer to the question of when life begins 
varies.  For example a geneticist may believe that the beginning of life starts when chromosomes 
from the sperm and the egg unite within the nucleus.  One the other hand, a developmental 
biologist might say that life starts at gastrulation, a point just after the embryo has been 
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implanted into the uterus of the mother (a key step for embryo survival). Whereas a neurologist 
may believe that life begins with the appearance of brain waves in the fetus at approximately the 
second trimester of pregnancy.  Brain waves represent an intriguing biological marker of life, as 
a lack of brain waves marks the legal definition of death in many jurisdictions (“Stem Cell 
Research…”, 2005). Yet questions still remain. Does human life begin at birth?  Does it start at 
conception?  To be quite honest, there is no wrong answer. At this point it depends upon an 
individual’s religious belief, views on scientific doctrine, and personal opinion. 
 
Stem Cell Ethics and Religion 
 People’s beliefs on stem cells are not identical.  A given individual’s belief may vary 
depending on his/her country of origin or his/her religion.  Different countries have enacted 
various policies on stem cells (Figure-1).  For example, England, Sweden, Finland, India, China, 
and Australia have enacted broadly encompassing policies that allow embryo donations for 
research purposes, the derivation of ES cells from fertilized embryos, and human therapeutic 
cloning.  Alternatively, countries such as Chile, Mexico, Greenland, Africa, Saudi Arabia, Tibet, 
and Malaysia have enacted no stem cell policies. Since a particular nation’s stem cell policy is 
strongly affected by that nation’s predominant religion, most of our discussion will focus on the 
various religious stances on stem cells.   
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Figure-1: World Map of Various Stem Cell Policies.   Yellow: Country with 
no stem cell policy; orange: IVF donations allowed; grey: country with 
restrictive stem cell policies; burgundy: various stem cell techniques are 
allowed.   (“A Global…,” 2009) 
 
With respect to various religious beliefs, the question of when life begins is especially 
important for their standpoint on ES cell research.  The Roman Catholic Church provides some 
of the greatest opposition to using any human embryos for research, because Catholic belief 
holds that “life is sacred from the moment of fertilization, and the embryo is the inception of 
personhood no matter where it exists” (“Stem Cell Research,” 2005).  In addition, the Orthodox 
Christian and Methodist churches believe that embryo research is a violation of human life 
(Scott, 2006).   On the other hand, a majority of Protestants hold that stem cell research should 
be allowed as long as the embryos do not pass the fourteen or fifteen day window after 
fertilization when the fetus begins to take shape and the totipotency of the cells is lost. Many 
individuals are surprised to learn of this very strong dissent of views on stem cells within a major 
religion such as Christianity.  And even more shocking is that despite Catholic belief in life at 
conception, “in a Harris Poll conducted in August 2004, 73 percent of Catholics voted in favor of 
embryonic stem cell research; and only 11 percent were against it” (Scott, 2006). Thus, some 
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Catholic individuals still believe that the benefits of ES cells toward aiding humanity outweigh 
the risks to the embryo, even if the formal Catholic stance is against such cells. 
As for the Islamic community, Muslims believe that life begins on the 40
th 
day of 
development after fertilization. There is no explicit ruling for Islamic views on stem cell 
research, however adherents to this religion believe that since an embryo is not in the womb, it 
will not survive and develop into a human being.  Thus, many in the Islamic community support 
embryonic stem cell research, especially if this research has the potential to cure diseases 
(Siddiqi, 2002).  More intriguingly, Islam makes a distinction between the early stages of 
pregnancy (composed of the first 40 days post-fertilization) and the embryo’s later stages. For 
example, if a pregnant woman in an early stage of zygote development is attacked and the baby 
is aborted, the attacker’s punishment will be less severe than if he committed the same act during 
full pregnancy. This distinction between early and late embryo development allows the majority 
of Sunni and Shiites to support ES cell research. 
Those of the Jewish faith also believe that human status is obtained after 40 days of 
gestation, and that the fetus only achieves personhood at birth. As a result, all of the major 
Jewish denominations support the use of embryos for research for therapeutic purposes.   
The Hindu belief is based on the idea that “… conception is the beginning of a soul’s 
rebirth from a previous life” (“Stem Cell Research,” 2005), thus individuals with this belief are 
generally against ES cell research.  But despite this fact, Hinduism has no official position on 
stem cell research, and many Hindus tend to support the therapeutic benefits of ES cell research 
for the betterment of humanity.  Buddhists also believe that the beginning of life starts at 
conception. Many Buddhists believe that ES cell research is in accordance with the Buddhist 
tenet of seeking knowledge and ending human suffering. Others view it as a disobedience to the 
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Buddhist belief of not harming others. Thus some Buddhists support ES cell research while 
others do not (Vestal, 2008). 
Thus, with respect to religion and stem cells, a surprising five out of five of the primary 
religions across the world are not completely against ES cells.  The religions most strongly in 
favor of ES cell research are those religions that argue life begins at day 40, for this time is well 
after the 5 day period necessary to obtain a blastocyst to derive the ES cells.  It is also important 
to note that all major religions support the use of adult stem cells to save lives, as no embryo is 
destroyed to obtain these cells.  However, it is true that some individuals within a few religious 
denominations are against the use of ES cells. Thus, individuals who feed off of the media’s 
hype and claim that they are against all stem cell research as a result of their religion are 
sometimes misinformed about their own religion. Indeed, with the exception of the formal 
Catholic stance, none of the major religions reject ES cell research outright, and thus believe in 
furthering a greater good for humanity through stem cell research. 
 
The Moral Status of an Embryo: Does Destroying a Blastocyst to Obtain ES Cells 
Constitute Murder? 
Opponents of stem cell research believe that removing the inner cell mass from an 
embryo is like murdering a child to save others’ lives. Individuals such as Senator Sam 
Brownback of Kansas believe that “it is never acceptable to deliberately kill one innocent human 
being to help another” (Sandel, 2007).  His logic follows Kantian ethics that “persons should 
never be used as a means for someone else’s ends” (Scott, 2006).  If embryos are indeed persons, 
destroying an embryo for scientific research would be equivalent to killing a child. But are 
embryo’s truly human beings?  
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Those who support ES cell research enjoy stressing that the embryo from which stem 
cells are extracted is not human in form, nor is it implanted and growing in a woman’s uterus. 
Instead it is a blastocyst, “… a cluster of 180 to 200 cells, growing in a petri dish, barely visible 
to the naked eye” (Roleff, 2006).  Cells in this stage of development have not differentiated into 
tissue and organs, thus their usefulness lies in scientific experimentation for cell repair. It is only 
at the fourteenth day of fertilization that the cells lose their totipotency and begin to develop into 
an individual. This point is past the five day period necessary to obtain a blastocyst.  
Cells within an embryo are alive, but how many cells constitute a person? Is it the same 
as the number of grains of wheat that comprises a heap, an indeterminate value that varies by 
perception? An embryo is a being devoid of consciousness made up of a couple hundred cells 
whereas a human is a conscious being composed of many millions of cells. As Pulitzer-prize 
winning zoologist E.O. Wilson writes, “The newly fertilized egg, a corpuscle one two-hundredth 
of an inch in diameter, is not a human being. It is a set of instructions set adrift into the cavity of 
the womb” (Scott, 2006).  Therefore, an embryo and a human being are unlikely equivalents. 
Indeed many proponents of stem cell research point out the argument that just as an acorn is not 
an oak tree, human embryos and a developed human being are two different things (Sandel, 
2007).  
In determining whether or not an embryo is a living being, ethicists have also considered 
the idea of sentience, “the capacity to feel psychic or physical pleasure or pain”(Scott, 2006).  A 
being must be conscious of its existence to be sentient.  In different terms, “consciousness, 
whether it is explained behaviorally or neurochemically, is the experience of being a being” 
(Scott, 2006). Through experimentation it has been determined that major divisions of the mind 
are not formed until around four weeks after fertilization, and the brain’s first electrical activity 
 38 
does not occur until six weeks after fertilization.  However, the beginnings of a nervous system 
appear at around fifteen days after fertilization which is another reason why this time period is 
normally the cut off for embryo development in countries such as the United Kingdom (Scott, 
2006). 
As the idea of sentience implies, membership to a species is not the property that 
determines the moral status of a being. It is the psychological and cognitive traits that we 
associate with mature human beings that determine moral status which is why humans 
commonly regard dogs, cats, pigs, and other animals as having the moral statue of a person 
(Ethics of Stem Cell Research, 2008).  There are no guidelines for traits that comprise a human 
being.  However, in Philosopher John Locke’s terms, embryos are not people, as he believes  it is 
“trying to find some capacity - perhaps self-awareness, reasoning power, or sense of oneself as 
having a history - that marks the point at which human beings become persons (or cease to be 
persons)” (Scott, 2006). 
Despite their lack of cognitive awareness, embryos deserve to be thought as more than 
just things, as they are a potential human life. Indeed, “the life of a single human organism 
commands respect and protection … no matter in what form or shape, because of the complex 
creative investment it represents, and because of our wonder at the divine or evolutionary 
processes that produce new lives from old ones” (Ethics of Stem Cell Research, 2008). Yet, this 
fact should not prevent research from occurring. For example, “If we were persuaded that 
embryonic stem-cell research were tantamount to infanticide, we would not only ban it but treat 
it as a grisly form of murder and subject scientists who performed it to criminal punishment” 
(Sandel, 2004).  Indeed, “… an extracorporeal embryo - whether used in research, discarded, or 
kept frozen - is simply not a precursor to any ongoing personal narrative. An embryo properly 
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starts on that trajectory only when the gamete sources intentionally have it placed in a womb” 
(Espejo, 2002).  In fact, the 5-day-old blastocyst from which hESCs are obtained is “a few dozen 
cells that together are too small to be seen without a microscope. (They have) no conclusions, no 
self-awareness, no ability to feel love or pain. The smallest insect is far more human in every 
respect except potential” (Roleff, 2006). 
Other opposition to ES cell research comes from philosophers that believe that science 
should withdraw to simpler, more familiar practices. Other individuals believe that embryonic 
stem cell research will be used for human enhancement instead of for therapeutic reasons.  As 
ethical council member Michael Sandel states, “the trouble with biotechnology is that it 
represents the one-sided triumph of willfulness over giftedness, of dominion over reverence, of 
molding over beholding” (Scott, 2006). Similarly, many worry that stem cell research will evolve 
into dehumanizing practices “such as embryo farms, cloned babies, the use of fetuses for spare 
parts, and the co-modification of human life” (Sandel, 2007). However, though these worries 
could be valid in the eventual future, adopting regulatory safeguards for stem cell research will 
prevent it from being exploited in such a disturbing manner. 
Such limitations would include the following.  Human embryos should only be used in 
research if the research goals cannot be obtained with alternate means, such as the use of adult 
stem cells. Stem cells should be used only under stringent laws regulating how long the embryos 
can be allowed to grow, where these embryos can be obtained, and how embryonic stem cell 
research can be applied.  An example of this legislation is the UK’s Human Fertilization and 
Embryology Act of 1990 that allowed scientists to only use human embryos that had not 
developed past fourteen days (Furcht and Hoffman, 2008). Researchers should avoid buying and 
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selling embryos as property, and should recognize that the destruction of an embryo should be 
respected and provoke a sense of regret (Espejo, 2002).  
 
Embryos and IVF Clinics 
Some believe that “… if it is immoral to sacrifice embryos for the sake of curing or 
treating devastating diseases, it is also immoral to sacrifice them for the sake of treating 
infertility” (Sandel, 2004). However, proponents of in vitro fertilization (IVF) emphasize that 
embryo loss in IVF pregnancies is less frequent than in natural pregnancy. Indeed more than half 
of all fertilized eggs in normal pregnancies fail to implant or are otherwise lost.  With such a 
high natural mortality rate, the loss of an embryo should not be considered the infanticide many 
view it to be.  Indeed strict religious burial rituals and mourning rites are not mandated or 
performed for the loss of an embryo as they are for the loss of an infant.  The diverse way 
humanity naturally responds to the loss of an embryo compared to an adolescent implies that the 
embryo’s death is not the moral equivalent of a child’s. Moreover, if the embryo loss from 
natural reproduction were equal to the death of a kid “…alleviating natural embryo loss would be 
a more urgent moral cause than abortion, in vitro fertilization, and stem-cell research combined” 
(Sandel, 2004).  
Yet the ethical question still stands, if the production of embryos for IVF clinics is 
morally acceptable, why is the creation of embryos for stem cell research unacceptable? Around 
400,000 unused frozen embryos reside within the U.S. IVF clinics (Sandel, 2007), with 
approximately 19,000 excess frozen embryos added each year (Espejo, 2002). After all, curing 
diseases such as Parkinson’s and cancer is at least as important as fixing infertility (Sandel, 
2007).  Indeed, it is surprising how many individuals in the U.S. alone could benefit from 
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potential stem cell treatments. For example, approximately 58 million Americans suffer from 
cardiovascular disease, another 30 million from autoimmune diseases, 16 million from diabetes, 
10 million from osteoporosis, 8.2 million from cancers, 5.5 million from Alzheimer’s, and 5.5 
million from Parkinson’s (Roleff, 2006). Since ESC research aims at curing these illnesses, 
“those who create embryos for research no more aim at destruction or exploitation than those 
who create embryos for fertility treatments aim at discarding spares” (Roleff, 2006).  As a result, 
excess IVF clinic embryos that will eventually be discarded are viewed as a valid alternative for 
obtaining embryos for ES cell research, and this is reflected in President Obama’s July 2009 
policy on stem cells currently in effect in the U.S. (discussed in Chapter-4). 
 
Adult Stem Cell Ethics 
Adult stem cells (ASCs) were first discovered over fifty years ago with the 
characterization of hematopoietic forming cells present in bone marrow (reviewed in Horowitz, 
1999).  Some believe that adult stem cells are just as promising, or in some cases more 
promising, than ES cells due to the fact that they do not destroy an embryo.  Indeed, some 
individuals find ES cell research unnecessary for the advancement of medical practices. 
However, despite the fact that ASCs yield promising research and clinical success (as 
discussed in Chapter-1), these cells are not the biological or medical equivalents of ES cells. 
ASCs have been isolated from bone marrow, skin, mesenchyme, skin, and brain, but not from all 
tissues of the body.  ASCs can self-renew and replace damaged tissue for only certain specific 
forms of tissue in which they reside. As Verfaillie noted, “the fact is that stem cells from 
fertilized eggs have the ability to grow into any type of cell or organ in the body. Adult tissue 
stem cells appear to have a much more restricted path for development, limiting their usefulness 
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in therapies of specific diseases” (Roleff, 2006).  As a result, many scientists still believe that the 
potential for fighting diseases lies in ES cell research, until proven otherwise. 
 
iPS Cell Ethics 
Induced pluripotent stem (iPS) cells are one of the newest, most popular, and most 
promising variety of stem cells being researched today.  iPS cells appear to be pluripotent stem 
cells, but they are formed without the destroying an embryo. Instead, genes within somatic cells 
are reprogrammed to create these cells via de-differentiation.  In some studies, iPS cell lines 
function similarly in comparison to ES cell lines, however more recent studies question their true 
pluriopotency (Dolgin, 2010).  Soon after their 2007 discovery (Takahashi et al., 2007), early 
studies indicated iPS and ES cell populations grow at the same rate; telomerase is present in 
both, and several genes active in ES cells and silenced in fibroblast cells are active in iPS cells. 
As stem cell researcher James Thomson states, “the human iPS cells described appear to meet 
the defining criteria we originally proposed for human ES cells, with the significant exception 
that iPS cells are not derived from embryos” (Deem, 2009).  Thus, these iPS cells appear to have 
the potential to be a moral substitute for hES cells, but further research will be required to prove 
this point.  Nevertheless, even if iPS cells prove to be slightly less potent than ES cells, they may 
still represent a means for treating some diseases without destroying embryos. 
 Unfortunately, this new stem cell technique has a number of drawbacks.  In the original 
2007 study (Takahashi et al., 2007), one of the genes used for reprogramming (c-MYC) 
produced an increase in tumors and cancers, although subsequent experiments successfully 
formed iPS cells in the absence of c-Myc (Nakakawa et al., 2008). Another problem with iPS 
cells in the earlier studies is that the genes for iPS cell production were introduced using a 
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retrovirus that incorporates into the host cell DNA.  This process is unstable, for depending on 
where the gene sequence inserts, it can cause random mutagenesis. However, newer techniques 
for iPS creation have eliminated the problematic c-MYC gene and switched to a lentivirus 
reprogramming system or, in some cases, have eliminated viral delivery altogether through 
reprogramming genes cloned into a circular piece of DNA called a plasmid (Stadtfeld et al., 
2008; Deem, 2009).  
 IPS cells have already been used to treat some diseases in mouse models.  Indeed, “a 
team from Rudy Jaenisch’s lab at the Whitehead Institute, along with a group led by Tim 
Townes at UAB, announced in Science that it has used induced pluripotent stem cells to treat 
sickle cell anemia in mice” (“iPS Cell Therapy,” 2007).  Yet, embryonic stem cells still seem to 
be the gold standard.  As Jaenisch states, “all the progress in this field was only possible because 
we had embryonic stem cells to work with first.  We need to make more ES cells and really 
define which are going to be the best ones for different applications” (“IPS Cell Therapy,” 2007). 
Overall, iPS cells have the potential to be a safe and effective stem cell treatment for 
some diseases, even if they are not quite ES cell-equivalent. Even the President’s Council on 
Bioethics called iPS cells “ethically unproblematic and acceptable for use in humans” (Gorelick, 
2009).  Moreover, it is apparent through the iPS cells produced in various laboratories across 
America that this technique is powerful and easily reproducible.  Thus, through the correction in 
many of the initial 2007 drawbacks to inducing iPS cells, iPS techniques hold the potential to 
soon possibly replace ES cells for therapies. 
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Chapter-3 Conclusion 
Since a major goal of stem cell research is to create cell-based therapies for human 
diseases, the lack of support for embryonic stem cell research is distressing. This is especially 
true considering “… one reason that evidence was lacking that hES cells could treat Parkinson’s 
and other problems was due, in part, to a decades-long U.S. government ban on embryo research. 
Without embryos as a source of ES cells, knowledge is scarce” (Scott, 2006). Indeed, a stem cell 
scientist complained to Newsweek during the Bush administration’s ban on ES research that the 
government’s restrictions on ES cell research to only a few ES cell lines derived prior to 2001 is 
“like forcing us to work with Microsoft version 1.0 when the rest of the world is already working 
with 6.2” (Furcht and Hoffman, 2008). With legislature under the Bush administration, there 
were only 15 stem cell lines available, a number many claimed is not an adequate for current 
research.  And a few of these 15 lines have already been exhausted.  Indeed many scientists 
believe that politics more than ethics stood behind the Bush White House 2001 legislation 
preventing the funding of new hESC lines. More recently, due to Obama’s stem cell policy 
instituted as of July 2009, the lack of usable ES cell lines has improved (discussed in Chapter-4), 
but the overall low number still remains a problem.   
  Even though many would say that killing an embryo is morally problematic, an embryo 
lacks self-awareness, moral sense, and rationality. If there is a chance that an embryo can 
improve the lives of numerous human beings where traditional medicine cannot, I do not believe 
that a small mass of cells should stand in the way of extending their life. Personally, I am for 
using embryos under any circumstance and agree with James Petersen, Professor of Ethics and 
Theology, who posed the written argument, “how can we let patients who are unmistakably 
people die to protect embryos that, even if implanted may or may not turn out to someday 
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become person? We should not kill people to benefit others, but we should also not let people die 
to protect tissues such as sperm or ova, even though such gametes have great potential” (Scott, 
2006). 
Though I am not against the idea of using embryos solely for research purposes, I do 
believe that if it is possible to get embryos from IVF clinics we should do so there first, before 
resorting to using embryos from paid donors. After all, embryos as living entities should be used 
sparingly and with respect.  In addition, with such large quantities of excess IVF embryos, ES 
cell research should be allowed to continue on donated, frozen IVF embryos that would 
otherwise perish without a contribution to society.  Indeed, in 1999 it was estimated that more 
than 150,000 frozen embryos were stored in IVF clinics with 19,000 added each year (Espejo, 
2002). 
However, as a nod to those who find that using embryos to create potentially lifesaving 
stem cell lines is murder, I believe in using ASCs whenever possible.  There is no reason for 
using embryos unnecessarily, and purposefully aggravating other’s sense of morality. Yet I do 
not believe that ASCs should be used all of the time, especially if subsequent ASC treatments 
prove to be less potent than ES treatments for treating a particular disease.  There are medical 
advantages to using hESC stem cell lines for therapies.  Until hES cells can be safely replaced 
with adult or iPS stem cells in treatments currently using hESC, it makes sense to continue ES 
cell research. Once we hit this point, hESCs may become obsolete, and there will be no need for 
the questionable ethics surrounding them.  
As for the revolutionary iPS cell research, I am in favor of its continuation, but uncertain 
as to whether iPS cells will prove to be medically equivalent to ES cells. However, with the rapid 
advances scientists have made in only a few years with iPS cells, I believe that they eventually 
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will become a moral substitute for ES cells.  If anything, research on iPS cells should be 
enthusiastically supported as a promising supplement for the far more controversial use of hES 
cells in medical research. 
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Chapter-4: Stem Cell Legalities 
 
The intent of Chapter 4 is to discuss the impact of technology on society through the laws 
controlling stem cell use in America and around the globe. Three different presidential 
administrations, Clinton, Bush, and Obama, have had an influential impact on regulations for 
embryo and stem cell research in the United States.  Overall, the United States has been rather 
unsupportive and restrictive with its stem cell legislation in comparison to Europe and Asia. 
When federal funds were lacking, states have occasionally circumvented this by creating their 
own stem cell legislation. Indeed, despite legal restrictions, most Americans feel that ESC 
research has the potential to benefit medical practices, and the United States is falling behind in 
the stem cell race. 
 
Early U.S. Stem Cell and Embryo Policies 
 The advent of in vitro fertilization (IVF) in the late 1960’s began a national debate about 
the fate of fertilized embryos that were initially created for reproductive purposes but were not 
implanted.  The extra embryos were usually discarded, so the debate focused on whether they 
could be used for research purposes.   Additionally, at this time, abortions became more 
prevalent, so discussions also focused on whether tissues isolated from aborted fetuses could be 
used for research purposes.  In 1974, the National Commission for the Protection of Human 
Subjects of Biomedical and Behavioral Research, initially appointed by President Nixon, 
recommended a ban on all federally funded research using embryos and fetal tissues.   The 
recommended ban was subsequently enacted by congress.  In 1975, President Ford appointed an 
Ethics Advisory Board to make recommendations on embryo and fetus research, but in 1981 
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newly elected President Reagan ended the ethics board’s charter. This resulted in a defacto 
moratorium on funding for ESC research, and allowed the original 1974 ban to continue (Stem 
Cell Tracker, 2009; Wanjek 2009). Congress tried to override this moratorium in 1992, but 
George H. W. Bush vetoed it (Wanjek, 2009). 
 
Clinton Administration Stem Cell Policies (1993-2001) 
Once Clinton began his presidency in 1993, he lifted the moratorium on ESC funding put 
in place by Ronald Regan (Wanjek, 2009). By doing so, President Clinton gave NIH the 
authority to fund embryonic stem cell research for the first time (Dunn, 2005; Scott, 2006). The 
first step NIH took was to establish a panel of ethicists, scientists, and public policy experts to 
evaluate what types of experiments should be qualified for federal funding (Dunn, 2005). In 
1994, the NIH Human Embryo Research Panel advised President Clinton to allow federal 
funding for research on left over IVF embryos, and suggested that funding be allowed for 
research on embryos created specifically for experimentation as well. Yet, moral and ethical 
issues/outcrys from prolife supporters caused President Clinton and his administration to agree to 
fund only stem cell research on excess embryos from IVF treatments. To further evaluate the 
ethical issues surrounding stem cells and other biotechnology, Clinton established the National 
Bioethics Advisory Commission (NBAC) in 1995, and gave an executive order that they review 
the policies and procedures involving “human subjects research, the use of genetic information, 
and gene patenting” (“BIO,” 2005). 
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1995 Dickey-Wicker Amendment 
However, Congress at this time thought that any work with human embryos was too 
radical. Thus in 1995, in response to Clinton’s support of ESC research, Congress passed a rider 
attached to the appropriations bill for the Department of Health and Human Services entitled the 
Dickey-Wicker Amendment, which prohibited any federal funding for embryonic stem cell 
research regardless of the source of the embryo (Dunn, 2005; “Stem Cell Laws,” 2010). 
Congress has renewed this ban every year since its establishment, until 2009 when newly elected 
President Obama overturned it for IVF embryos.  Thus, taxpayer money until 2009 could not be 
used for any embryo experiment, and post-2009 cannot be used to create an embryo solely for 
research purposes. 
In 1997, Clinton proposed a reproductive cloning ban with civil penalties based on 
NBAC recommendations, but Congress adjourned without taking any action (“BIO,” 2005). A 
year later, the discovery of hESCs from privately funded research led to another flurry of stem 
cell politics. At this time the Senate considered and rejected legislation that banned all human 
cloning including therapeutic. Also, BIO (Biotechnology Industry Organization) along with 200 
patient and voluntary health groups called for the doubling of the $13.6 billion NIH budget 
within five years. With the sudden rise in advances within biotechnology, Congress was 
receptive to their plea, and by 2001 the NIH budget had already risen to $20.3 billion (“BIO,” 
2005).   
 
2000 Loophole in Dickey-Wicker Amendment 
Eventually, the NBAC, created by Clinton, provided a list of reasons why the ban on 
stem cell research should be lifted, such as shortening the time to clinical trials and promoting 
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competition among biotechnology companies in order to decrease health costs.  With respect to 
the moral status of the embryo, the NBAC wrote, “The embryo merits respect as a form of 
human life, but not on the same level accorded to humans” (Scott, 2006).  However, with the 
Dickey Amendment in place, the government could not support research used to derive stem cell 
lines.  Luckily, Harriet Rabb, the top lawyer at the Department of Health and Human Services, 
found a loophole stating that hESCs “are not a human embryo within the statutory definition,” 
and thus the Dickey Amendment does not apply to them.  As a result, in 2000, President Clinton 
endorsed guidelines to allow NIH to accept grant proposals from scientists experimenting with 
previously derived hESC stem cell lines.  In doing so, although no embryos could be destroyed 
with government finances, NIH funding could be used to research on established hESC lines 
formed from private dollars.  Thus, the Clinton Administration was the first to open the door to 
federal funding for ESC research. Unfortunately, no grants were ever provided under the 
guidelines as they were put on hold when President Bush took office in 2001 (“BIO,” 2005; 
Dunn, 2005). 
 
Bush Administration Stem Cell Policies (2001-2009) 
 
August 9
th
 2001 Policy 
In 2001, President Bush took office and canceled the NIH review of stem cell grant 
applications for re-evaluation.  (“BIO,” 2005; Dunn, 2005).  On August 9th 2001, Bush made a 
televised decision to allow federal funding only for a list of pre-existing hESC lines. These lines 
were allowed, as an embryo had already been destroyed for their creation.  But to discourage any 
further embryo destruction, Bush stated that federal taxpayer money would not be allowed for 
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research on stem cell lines formed after August 9th of 2001.  Many scientists and patient groups 
took issue with the limitation on stem cell lines. However, privately funded hESC research still 
remained possible (Kruse, 2008).  
With respect to the number of human ES cell lines available for federally funded 
research, at the time of Bush’s address to the nation, NIH stated that there were 64 stem cell lines 
eligible for federal funding.  Three months later, the NIH Human Embryonic stem Cell Registry 
was posted listing all of the cell lines available for federal funding (Kruse, 2008), but there is a 
discrepancy in the number of cell lines listed in this report: some sources say that the registry 
approved over 70 lines, while others  mention numbers in the 60’s.  However, after genetic and 
growth testing were performed on the cell lines, only around 10-20 lines ended up being usable 
for ESC research (Babington, 2006; Scott, 2006; Kruse, 2008); some lines perished after being 
removed from the freezer, some lines were duplicates, some stopped growing, and others existed 
in 10 worldwide organizations outside the US.  For the more than thirty lines residing outside the 
US, James Battey, the NIH official who administered the registry, stated, “We have no indication 
that any of these institutions will ever seek NIH support to develop their lines, or will make any 
effort to distribute their lines to the research community” (Scott, 2006).  
The major issue with a majority of the hESC lines offered for federal funding was that 
these lines had been co-cultured with a feeder layer of animal cells (usually mouse fibroblasts) 
which contaminated the hES cells with animal proteins.  Researchers prefer to work only with 
human cells as there is a concern that mouse viruses could contaminate the lines and harm 
humans (Babington, 2006; Scott, 2006). Also, human antibodies attack hESC’s grown with 
mouse cells, leading to a severe immune rejection that could be prevented using purely human 
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stem cell cultures (Scott, 2006). Thus, most of the promised ES cell lines could not be used for 
biomedical research.  
 
2001 Weldon Legislation and Brownback Bill 
Later in 2001, the House of Representatives followed the White House ethics panel and 
created a bill known as the Weldon legislation that would ban the cloning of humans and 
criminalize all SCNT techniques used for therapy or otherwise. Bush backed the bill stating, “I 
strongly support a comprehensive law against all human cloning. And I endorse the bill 
wholeheartedly” (Scott, 2006). If this bill had passed, scientists caught using human SCNT 
would have been subject to a penalty of $1 million and up to ten years in jail. In addition, 
Senators Sam Brownback and May Laudrieu introduced a proposal in support of the House’s bill 
with the provision (known as the Brownback bill) that the same criminal penalties be established 
for any American who provided or received medical treatments involving SCNT techniques 
developed in another country. Many individuals were outraged, as Nobel Prize winner Paul Berg 
states in reaction to the Weldon legislation “I couldn’t believe the arrogance of a bunch of people 
in congress saying to 290 million Americans, sorry folks, you’re not going to have the therapies 
to cure your disease because we are offended by this technology” (Scott, 2006).  Luckily, this 
bill was not passed after congressional debates ensued over advise from BIO and other 
biotechnology companies (“BIO,” 2005).  Indeed, although a ban on reproductive cloning was 
supported by scientists and biotechnology agencies, banning therapeutic cloning would have cost 
Americans potential medical cures.  
 
 
 54 
President’s Council on Biomedical Ethics 
In 2001, Bush also created a new bioethics council to further advise him on stem cells 
and other ethical issues. This council, known as the President’s Council on Biomedical Ethics 
(PCBE), was headed by University of Chicago professor Leon Kass (“BIO,” 2005; Scott, 2006). 
In July of 2002, the first PCBE recommendations on stem cell research arrived in a report titled 
Human Cloning and Human Dignity.  In this statement, seventeen out of eighteen members 
voted to ban reproductive cloning. On the other hand, in relation to the issue of whether to 
support therapeutic cloning, the council voted ten members to seven, with one abstention, for a 
four-year moratorium on the issue (Scott, 2006).  
Some worry that President Bush stacked his Council to support his policies. This idea 
may have some grounds.  Since the PCBE’s decisions in 2002, three members left the PCBE; 
one was removed, another resigned, and the third’s term was not renewed. All of these 
individuals were supporters of ESC research. In addition, Janet Rowley, a member of the PCBE 
stated, “I have seen firsthand through the president’s council that this administration distorts 
scientific knowledge on stem cell research, which makes it increasingly difficult to have an 
honest debate in a field that holds promise for treatment of many serious diseases like 
Parkinson’s and juvenile diabetes” (Scott, 2006). Also, in reaction to the rearranging of the 
PBCE, the president’s spokesperson stated evasively that Bush had “decided to appoint other 
individuals with different expertise and experience” (Scott, 2006). The Union of Concerned 
Scientists representative, Henry Waxman, noticed that political interference in science agency 
appointments also occurred in a number of other areas, including the NIH, NASA, EPA, and the 
FDA.  More intriguingly,  the World Health Organization protested that it had to ask for HHS 
permission each time it needed a US government advisor, rather than just contacting experts 
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directly as it has in the past (Scott, 2006). Indeed, as bioethicist George Annas wrote in response 
to the Bush administration, “Bioethics in the United States reflects US culture and tends to be 
pragmatic, market-oriented and insular” (Furcht and Hoffman, 2008).  
By 2003, Congress had begun to notice that younger, talented scientists had started to 
leave the country to conduct their research in an environment with fewer stem cell research 
restrictions.  England, in particular, was one of the most attractive areas for American scientists 
looking to work on ESC research (Furcht and Hoffman, 2008).  As Keith Yamamoto, vice dean 
for research at the University of California, San Francisco School of Medicine states, “It’s too 
much work to put together a research proposal only to find out it’s going to be made illegal, or 
that there will be a four-year moratorium proposed” (Furcht and Hoffman, 2008).  At this time, 
the House introduced five stem cell bills, and the Senate two.  In 2004, a South Korean 
researcher reported on cloning their first human embryo, and this displayed how far behind on 
stem cell research the United States had internationally become (Scott, 2006). That same year, 
two hundred and six members of the House wrote a letter to Bush urging him to expand the 
number of stem cell lines allowed for federal funding.  In June, fifty-eight Senators sent a similar 
letter. However, Bush would not budge on stem cell research restrictions (Dunn, 2005; Scott, 
2006). Bush’s rigidity with stem cell restrictions was intriguing for, as Physician Sherman Elias 
states, “Current federal limitations on ESC research puts the United States at a competitive 
disadvantaged in comparison to other countries such as Great Britain. With a nation that takes 
such pride in being at the forefront of major technological breakthroughs, and with a rising life 
expectancy, slacking on health care practices seems like a poor action for congress to make” 
(Furcht and Hoffman, 2008). 
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2005 Stem Cell Research Enhancement Act 
Regan’s death on June 5, 2004, due to complications of Alzheimer’s disease, and his 
widow’s advocacy of ESC research, sparked new public support and interest in reducing stem 
cell research restrictions (Furcht and Hoffman, 2008). Indeed, unlike the stem cell lines from 
2001, the new stem cell lines created with private funds were easier to access and maintain in the 
lab, were not contaminated with mouse cells, and differentiated into cells of interest more easily. 
Thus, the new ES cells were more likely to contribute to beneficial human therapies (Dunn, 
2005).  As a poll from the Civil Society Institute in February 2005 reveals, 70% of Americans at 
that time favored loosening Bush’s restrictions on stem cell policy in the US (Dunn, 2005).  In 
addition, in April of 2005, Bush’s NIH director Elias Zerhouni admitted that there is “mounting 
evidence” that a policy change would benefit science (Dunn, 2005). All of these events resulted 
in the introduction of the Stem Cell Research Enhancement Act in 2005. This bill would increase 
federal funding for ESC research and decrease federal restrictions on stem cell research by 
allowing federal government funded research on excess embryos from IVF clinics that had donor 
approval (Scott, 2006; Kruse, 2008).  Despite risk of a presidential veto, in May of 2005 the 
House of Representatives voted 238 to 194 to pass this bill (“Stem Cell Laws,” 2010).  In July of 
2006, the Senate also passed the act.  Unfortunately, Bush staunchly adhered to the stem cell 
policy he employed in 2001, and July 19 of 2006 Bush vetoed the act, frustrating supporters of 
hESC research (Furcht and Hoffman, 2008; “Stem Cell Laws,” 2010). Bush believed that “This 
bill would support the taking of innocent human life in the hope of finding medical benefits for 
others. It crosses a moral boundary that our decent society needs to respect. So I vetoed it. If this 
bill were to become law, American taxpayers would, for the first time in our history, be 
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compelled to fund the deliberate destruction of human embryos, and I’m not going to allow it” 
(Baker, 2005; Bash and Walsh, 2006).  
 The House attempted to override the veto, but the vote was 235 to 193, not the two-thirds 
majority necessary for the override (Baker, 2005; Bash and Walsh, 2006).  Bill Frist R-
Tennessee disagreed with Bush’s veto stating “I am pro-life, but I disagree with the president’s 
decision to veto the Stem Cell Research Enhancement Act. Given the potential of this research 
and the limitations of the existing lines eligible for federally funded research, I think additional 
lines should be made available” (Bash and Walsh, 2006).  Several leading Democrats also 
disapproved of Bush’s action. Indeed,  Senate Minority Leader Harry Reid (Nev.) said, 
“President Bush has made the wrong choice, putting politics ahead of safe, responsible science” 
and Sen. Edward M. Kennedy (Mass.) stated, “The President’s threat to veto legislation on 
bipartisan stem cell research demonstrates how out of touch he is with the priorities of the 
American people” (Babington, 2006). 
 
Stem Cell Therapeutic and Research Act of 2006 
 Although Bush banned an increase in federal research for embryonic stem cells, he did 
support furthering research on adult stem cells.  In fact Bush signed into law a Stem Cell 
Therapeutic and Research Act of 2006 written by New Jersey congressman, Chris Smith. This 
Act provided $265 million for adult stem cell therapy, umbilical cord blood and bone marrow 
treatment, and authorized $79 million for the collection of cord blood stem cells” (“Stem Cell 
Laws,” 2010).   Indeed, Bush stated “I am a strong supporter of adult stem cell research, of 
course. But I made it very clear to the congress that the use of federal money, taxpayers’ money, 
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to promote science which destroys life in order to save life is—I’m against that. And therefore, if 
the bill does that, I will veto it” (Babington, 2006). 
 
Obama Administration (2009-Present) 
During the Bush administration’s ban on federally funded embryo research, privately 
funded companies led the way in ES cell research at the expense of academic labs. But this 
changed in 2009 when Obama signed an executive order lifting an eight-year-old 2001 ban on 
federal funding of embryo research. Through doing so, President Obama ended limits on ESC 
research funding, and attempted to restore the “scientific integrity” of the American government.  
Obama said “It is about ensuring that scientific data is never distorted or concealed to serve a 
political agenda, and that we make scientific decisions based on facts, not ideology” (Childs and 
Stark, 2009; Windslow and Naik, 2009).  Indeed, through his act, the president renewed hope for 
new ESC research and support for ESC scientists (Childs and Stark, 2009). 
The president-signed executive order gave the National Institutes of Health 120 days to 
compile new guidelines for the manner in which ES cell research was to be carried out (Childs, 
2009; Windslow, 2009). The guidelines should address issues such as where embryos used for 
research should come from, and how consent must be obtained from those who donate them. In 
addition to supporting ES cells, Obama promised to support the “groundbreaking work” being 
done on adult stem cells and IPS cells that conservatives advocate (Windslow and Naik, 2009).  
However, though loosening restrictions, Obama stated that the government will not 
undertake ESC research lightly, and emphasized that he will support the necessary ethical 
restrictions that will promote the responsible use of stem cell research and technology.  Initially 
Obama’s policy would not affect federal laws that prevent the use of federal funds to destroy 
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human embryos (Childs, 2009), so while it would broaden research opportunities on hundreds of 
privately established cell lines, Obama’s executive order would not promote the creation of new 
ones.  But Obama’s initial policy may be modified in view of the NIH Guidelines to allow the 
creation of new ES cell lines under strict rules mandating donor consent for IVF embryos 
initially created for reproductive purposes (Lo et al., 2010).  In addition, Obama’s stem cell 
policy is designed so that it “never opens the door to the use of cloning for human reproduction” 
(Borenstein and Feller, 2009).  This particular type of reproductive cloning he considers as 
“dangerous, profoundly wrong, and has no place in our society or any society” (Borenstein and 
Feller, 2009).  
Obama feels that a majority of Americans support his lifting of the federal funding ban, 
as this allows the government to support researchers, working with already derived hESC lines,  
to uncover  revolutionary cures for cancer, heart disease, Parkinson’s and other illnesses. Obama 
says “In recent years, when it comes to stem cell research, rather than furthering discovery, our 
government has forced what I believe is a false choice between sound science and moral values. 
In this case, I believe the two are not inconsistent” (Borenstein and Feller, 2009; Childs and 
Stark, 2009; Wilson, 2009).  Harvard Stem Cell Institute co-director, Doug Melton, supports 
Obama’s stem cell policy stating “On a personal level, it is an enormous relief and a time for 
celebration… Science thrives when there is an open and collaborative exchange, not when there 
are artificial barriers, silos, constructed by the government” (Borenstein and Feller, 2009).  Most 
scientists also support Obama, and hope that the policy change will provide a boost for ES cell 
research, attract young scientists to the field, and permit America to establish leadership in an 
area currently headed by Europe and Asia. "We have a long way to go in understanding the basic 
biology of human embryonic stem cells," said Arnold Kriegstein, who heads stem cell research 
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at the University of California at San Francisco,"Now that the policy has changed we'll see a 
resurgence in academic activity" (Windslow and Naik, 2009). 
Unfortunately one year after President Obama lifted Bush’s restrictions on hESC 
research, scientists began complaining that the new policy is paradoxically more harmful than 
helpful to their work.  By loosening restrictions on federal funding, Obama opened new ethical 
issues with NIH’s ethical recommendations in their published guidelines (Lo et al., 2010).  As a 
result, the new NIH guidelines state that hESC lines being studied with federal funding must 
meet strict new ethical criteria. However, it is unclear which of the 21 previously approved pre-
2001 ES lines researchers have spent millions of dollars working on fit the new NIH criteria, 
especially since many of these lines were developed at a time when ethical requirements were 
not as advanced (Stein, 2010). “Some of these lines were derived more than a decade ago, and 
some of the researchers who derived them aren’t around anymore. Some of those records 
[proving donor consent and IVF origins] may not be available,” states Timothy J. Kamp, director 
of the stem cell and regenerative medicine center at the University of Wisconsin (Stein, 2010). 
So far, the NIH has approved 43 lines, but only one of the 21 Bush lines. One hundred 
and fifteen lines are still waiting for review, but of these lines only two Bush lines are included. 
“We’re losing access to those lines in this approval process for some period of time—maybe 
indefinitely. They are the main workhorses for many of our projects” Kamp says (Stein, 2010). 
However, scientist hope that the NIH will alter their guidelines and allow a 2-year grace period,  
so that scientists can continue their research until they get formal approval to use their stem cell 
lines again (Stein, 2010).   In any case, even under the new strict NIH ethical guidelines, 
researchers already have more ES lines available for research than under the Bush 
administration, and the number continues to rise. 
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Individual State Stem Cell Laws 
 Although some previous administrations have placed bans on using federal funding for 
embryo research, individual states can pass their own legislations funding embryo research.  This 
tactic was especially developed during the Bush administration’s 2001 ban.  Figure-1 shows a 
map of the US with individual states shown in colors.  States shown in blue led the way for 
approving state bonds to fund stem cell institutes and to fund embryo and stem cell research.  
States shown in pink restricted ES research as of 2005. 
 
Figure-1:  Map of Stem Cell Legislation in the US by State.  (“Stem 
Cell Legislation in the US by State,” 2005) 
 
In 2002, Governor Gray Davis of California declared that the state was a “restriction-free 
zone”, and signed a law allowing therapeutic cloning and embryo research, but banned 
reproductive cloning (Scott, 2006).  However, not until November of 2004 did California finally 
accompany the legislation with money through authorizing Proposition 71.  Proposition 71 
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allowed $3 billion, taxpayer funded, to support stem cell research over a period of ten years. The 
state was able to issue training grants, but legal issues slowed the distribution of research grants 
in 2006 (National Conference of State Legislatures, 2008). As a result, that same year, Governor 
Arnold Schwartzenegger loaned $150 million to support stem cell research. It took until May of 
2007 for the California Supreme Court to remove the last preventative to issuing $3 billion in 
bonds and allow the money to be used for research purposes (Furcht and Hoffman, 2008). 
Although California was the first state to support ESC research, New Jersey was the first 
state to pass a state budget for stem cell research. This occurred with the help of a neuroscience 
researcher at Rutgers University, Wit Young. Young helped legislature pass a bill in 2004, 
authorizing stem cell research to be done in New Jersey (Wadman, 2008).  In June of 2004, a 
$9.5 million budget was created for a newly contracted Stem Cell Institute of New Jersey 
(Godoy and Palco, 2006).  In 2005, $5 million in grants were split among seventeen research 
projects (Furcht, 2008). A year later $270 million was spent on supporting stem cell research, 
$150 million of which was used to build the Stem Cell Research Institute of New Jersey 
(Wadman, 2008).  New Jersey, like California, also supports therapeutic cloning and bans 
reproductive cloning.  
In Massachusetts, the Harvard Stem Cell Institute, established in 2004, was one of the 
primary motivators for developments in stem cell legislature.  In 2005, the Massachusetts 
legislature approved a bill that removed ESC researchers from the previously mandatory task of 
seeking approval from the local district attorney before conducting research. The bill also 
allowed therapeutic cloning but banned reproductive cloning. This legislation passed despite a 
veto from Governor Mitt Romney who does not believe in allowing SCNT practices 
(“Massachusetts Stem-Cell Bill,” 2005). At this time, Massachusetts legislators also added two 
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new sections to the statutes on stem cell research. One established an institute for stem cell 
research and regenerative medicine at the University of Massachusetts with an appropriation of 
$1,000,000 to be spent on the stem cell biology core. The second established a life sciences 
center and created the Life Sciences Investment fund to which $10,000,000 was appropriated 
(National Conference of State Legislatures, 2008). More recently, during the 2007 BIO meeting 
in Boston, Massachusetts Governor Deval Patrick pushed for a ten-year $1 billion investment in 
biotechnology, half of which would be used toward the creation of a Massachusetts Stem Cell 
Bank at the University of Massachusetts (Furcht and Hoffman, 2008; Wadman, 2008). This 
proposition passed making way for the construction of the nation’s largest stem cell bank. 
 In Connecticut, in 2005 the state approved legislation to allow and fund embryonic and 
adult stem cell research. The bill proposed giving $100 million to evolving research over a 
period of ten years (“Massachusetts Stem-Cell Bill,” 2005). 
 
World Policies 
The UK pioneered in vitro fertilization, supplying the world with excess IVF embryos for 
experimentation of hESC.  In 1990, the UK allowed ESC research on excess IVF embryos. Also 
in 1990, the British Parliament created the Human Fertilization and Embryology Authority 
(HFEA) to help regulate ESC research. Laws in Britain allow for the creation of embryos for 
research, but to work with hESCs scientists must obtain a license from the HFEA (Boyd et al., 
2009).  In 2001, England became one of the first countries to ban human reproductive cloning. In 
2002, the UK’s National Institute for Biological Standards and Control opened a stem cell bank 
to house stem cell lines created from adult, embryonic, and fetal tissues. The bank offers over 30 
stem cell lines (Furcht and Hoffman, 2008).  In 2004 the UK became the third country to allow 
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scientists to clone human embryonic stem cells for research purposes with SCNT. Recently, in 
May of 2008, British Parliament decided to permit research on experiments with animal-human 
hybrid embryos (Ralston, 2008). 
In 1999, Israel banned reproductive but not therapeutic cloning (Ralston, 2008). Later, in 
2001, Israel allowed the use of stem cells from early embryos and aborted fetal tissue up to nine 
weeks of age. Then, in 2004, Israel formed a multimillion-dollar consortium uniting five stem 
cell companies with the country’s leading academic labs (Scott, 2006).  
Sweden prohibits reproductive cloning and allows therapeutic cloning. This country has a 
well-established biomedical industry, and in 2002 the Swedish government authorized the 
creation of Europe’s second stem cell bank (Ralston, 2008). 
Germany has a restrictive policy for hESC research, due partly to its history of atrocious 
medical experiments under the Nazi regime. Indeed the creation of ESCs is prohibited. However, 
in April of 2008, Germany decided to allow the use of imported stem cell lines produced before 
May 1, 2007 for experimentation (Ralston, 2008). 
Australia’s 2003 cloning act permitted the development of hESC lines from excess IVF 
embryos created before April 5, 2002 for research. This act also banned both reproductive and 
therapeutic cloning (Garfinkle, 2004; Scott, 2006). 
The Chinese government has invested hundreds of millions of dollars in stem cell 
research to make itself a scientific superpower. For example the Tissue Engineering Research 
Center in Shanghai cost $260 million and seventy percent of this center was government funded 
(Boyd et al., 2009).  Not only does China have governmental financial support, but China also 
has one of the most liberal stem cell policies in the world, due in part to its Confucian culture 
that firmly believes human life begins at birth and not at conception (Boyd et al., 2009). Indeed, 
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China prohibits reproductive cloning but allows the creation of human embryos for medical 
research. China also permits scientists to conduct clinical trials for stem cell therapy on 
terminally or chronically ill patients (Ralston, 2008). In addition, China has scientific manpower 
due to the fact, as Robert Zhao, head of China’s National Center for Stem Cell Research states, 
”No country sends more of its students to America for higher education than China” (Furcht and 
Hoffman, 2008). 
As for stem cell policies in other parts of Asia, in 2007 India’s government banned 
reproductive cloning, but allowed experiments with therapeutic cloning. The Indian Council for 
Medical Research also set up guidelines for clinical trials with stem cells. So far, only stem cells 
for bone marrow transplants have been approved. Singapore is one of Asia’s stem cell epicenters, 
with over 40 stem cell research groups residing in the area. In order to boost their biomedical 
research, Singapore recruits scientists from around the globe, offering them the use of embryos 
no more than two weeks old for therapeutic research (Ralston, 2008). However, hESCs have to 
be taken first from existing cell lines, and then with medical merit subject to statutory review, 
embryos less than 14 days old can be created for research purposes (Scott, 2006). 
 
Chapter-4 Conclusion 
As the land of opportunity, the United States has a rather conservative stem cell policy 
compared to the best of the stem cell research hubs across the world.  But thanks to President 
Obama, American scientists can now use federal funding to research excess embryos from IVF 
clinics. However, ESC research in the US has not yet had time to recover from eight years of 
restrictive policies instituted by President George W. Bush.  Indeed, under the Bush 
administration, America was put in a biomedical research dark age as the hESC stem cell lines 
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allowable for federal funding were extremely outdated, and in many cases unfit for 
experimentation. America has become complacent with its technological success leading to 
excessive congressional squabbling over stem cell ethics. In a nation with a rising elderly 
population desperate for health care, it seems only natural that the federal government should 
supply support for improving medical procedures through stem cell research. As a nation we 
need to turn our arguments into actions to prevent further delays… or we will fall behind on 
more than stem cell research.  
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PROJECT CONCLUSIONS 
 
 
As ESCs have not yet been researched to their full potential, I believe that ESC research 
should continue until it has been proven that iPS cells can effectively replace ESCs in medical 
treatments.  Despite the fact that an embryo must be destroyed to obtain ESCs, I find ESC 
research falls into the category of doing a small amount of “evil” for a much greater good.  As I 
do not consider a blastocyst to be a full human being, I do not view embryo destruction at this 
stage as murder, but rather as a way to aid science in saving lives. Yet, though I do believe that 
the embryos should first be obtained from excess IVF embryos, before any embryos are 
produced in the lab solely for research purposes, or are obtained through paid egg donors.  I also 
believe that, whenever possible, iPS and ASCs should be used for experimentation as a substitute 
for ESCs in order to prevent unnecessary embryo destruction, as a nod to individuals who feel 
ESC research is morally abhorrent.  Indeed, I do believe that as a living being embryos deserve 
some moral respect. As to stem cell laws and federal regulations, I agree with Britain’s and 
Singapore’s stem cell policies. They encourage ESC research and allow the production of 
embryos solely for research, but first they promote obtaining embryos from other sources such as 
excess IVF embryos.  Thus, these countries regulate and limit the creation of embryos for 
experimentation while supporting ESC research.  Personally, I find that even under Obama’s 
administration, the United States is still too restrictive in their stem cell policies, by not allowing 
embryos to be created solely for research purposes. However, if iPS cells live up to their full 
potential, current US stem cell policies will not cause America to fall behind in the race to 
harness the power of the stem cell to benefit society.  
 
